Back to results
US 6,699,483 B1Granted
Cancer treatments
AssigneeOnyvax Limited
InventorsAngus George Dalgleish, Peter Michael Smith, Andrew Derek Sutton, Anthony Ian Walker
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeOnyvax Limited
InventorsAngus George Dalgleish, Peter Michael Smith, Andrew Derek Sutton, Anthony Ian Walker
Estimating the term…
The invention relates to a product comprised of specific combinations of cell lines intended for use as an allogeneic immunotherapy agent for the treatment of prostate cancer in humans. The heterogeneity of the immunotherapeutic matches the heterogeneity of the antigenic profile in the target prostate cancer and immunises the recipients with many of the potential TAA and TSA which are expressed at various stages of the disease. The invention discloses a vaccine comprising a combination of three different cell lines prepared from primary or metastatic prostate cancer biopsy material. The cell lines are lethally irradiated utilising gamma irradiation at 50-300 Gy to ensure that they are replication incompetent.
An allogeneic immunotherapeutic agent for the treatment of prostate cancer comprising three human prostate tumor cell lines of which one cell line is derived from a primary tumor and the other two cell lines are derived from metastatic tissue.
An allogeneic immunotherapeutic agent for the treatment of prostate cancer comprising a mixture of three human prostate tumor cell lines, wherein one cell line is derived from a primary tumor and the other two cell lines are derived from two different metastatic tissues.
An allogeneic immunotherapeutic agent for the treatment of prostate cancer comprising a mixture of three human prostate tumor cell lines, wherein three cell lines are derived from three different primary tumors.
An allogeneic immunotherapeutic agent for the treatment of prostate cancer comprising a mixture of three human prostate tumor cell lines, wherein two cell lines are derived from one or two primary tumor(s) and the other cell line is derived from a metastatic tissue.
An allogeneic immunotherapeutic agent for the treatment of prostate cancer comprising a mixture of three human prostate tumor cell lines, wherein three cell lines are derived from metastatic tissues.
An allogeneic immunotherapeutic agent for the treatment of prostate cancer comprising a mixture of three human prostate tumor cell lines, wherein three cell lines are derived from two or three different metastatic tissues.
An allogeneic immunotherapeutic agent for the treatment of prostate cancer comprising three different human prostate tumor cell lines, wherein one cell line is derived from a primary prostate tumor and the other two cell lines are derived from metastatic prostate tissue.
An allogeneic immunotherapeutic agent for the treatment of prostate cancer comprising three different human prostate tumor cell lines, wherein one cell line is derived from a metastatic prostate tissue and the other two cell lines are derived from primary prostate turmors.
Dependencies are inferred from the claim text.